Skip to main content
Top
Published in: Journal of Clinical Immunology 5/2016

Open Access 01-07-2016 | Original Article

Respiratory Health and Related Quality of Life in Patients with Congenital Agammaglobulinemia in the Northern Region of the UK

Authors: Branwen A. Bryan, Alex Battersby, Benjamin Martin James Shillitoe, Dawn Barge, Helen Bourne, Terry Flood, Andrew J. Cant, Catherine Stroud, Andrew R. Gennery

Published in: Journal of Clinical Immunology | Issue 5/2016

Login to get access

Abstract

Introduction

Patients with congenital agammaglobulinemia, characterized by a defect in B lymphocyte differentiation causing B alymphocytosis, require life-long IgG replacement. There is scant literature regarding the effectiveness of IgG treatment at preventing mucosal (particularly sinopulmonary tract) infection and whether current management adequately restores “normal” health and quality of life (QoL). We aimed to document infective episodes pre- and post-commencing IgG replacement, determine any change in lung function and structure and assess respiratory status and QoL in a cohort of patients treated in Newcastle.

Methods

Clinical data were extracted from medical records of 15 patients identified from the immunology database, focusing on infective episodes, serial chest CT and spirometry results. Thirteen patients completed a selection of standardized and validated questionnaires assessing physical health, respiratory health and QoL.

Results

Pediatric patients on IgG therapy suffered fewer infections per patient year (0.74) than adults (2.13). 6/14 patients showed deteriorating respiratory status despite adequate therapy. Health questionnaires revealed a significant burden of respiratory disease on a patient’s life.

Conclusion

Clinical data showed patients with congenital agammaglobulinemia receiving immunoglobulin therapy retained a higher than average infection rate, most of which affected mucosal barriers. Most patients self-reported worse respiratory symptoms, a lower respiratory-related QoL and a lower general health QoL relative to a healthy population. Most participants had progressive structural lung damage and decreased lung function. These results suggest that current management is not entirely effective at preventing deterioration of respiratory health or restoring QoL.
Literature
1.
go back to reference Fried AJ, Bonilla F a. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22(3):396–414.CrossRefPubMedPubMedCentral Fried AJ, Bonilla F a. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22(3):396–414.CrossRefPubMedPubMedCentral
3.
go back to reference Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J. Mutations in btk in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet. 1998;62(5):1034–43.CrossRefPubMedPubMedCentral Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J. Mutations in btk in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet. 1998;62(5):1034–43.CrossRefPubMedPubMedCentral
4.
go back to reference Hoernes M, Seger R, Reichenbach J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunol. 2011;22(8):758–69.CrossRefPubMed Hoernes M, Seger R, Reichenbach J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunol. 2011;22(8):758–69.CrossRefPubMed
5.
go back to reference Conley ME, Howard VC. X-linked agammaglobulinemia. GeneReviews(®). 2001; 1-13. Conley ME, Howard VC. X-linked agammaglobulinemia. GeneReviews(®). 2001; 1-13.
6.
go back to reference Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol. 2006;118(2-3):201–8. Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol. 2006;118(2-3):201–8.
7.
go back to reference Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221–30.CrossRefPubMed Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221–30.CrossRefPubMed
8.
go back to reference Janeway C, Apt L, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians. 1953;66:200–2.PubMed Janeway C, Apt L, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians. 1953;66:200–2.PubMed
9.
go back to reference Cellier C, Foray S, Hermine O. Regional enteritis associated with enterovirus in a patient with X-linked agammaglobulinemia. N Engl J Med. 2000;342(21):1611–2.CrossRefPubMed Cellier C, Foray S, Hermine O. Regional enteritis associated with enterovirus in a patient with X-linked agammaglobulinemia. N Engl J Med. 2000;342(21):1611–2.CrossRefPubMed
10.
go back to reference Soresina A, Nacinovich R, Bomba M, Cassani M, Molinaro A, Sciotto A, et al. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol. 2009;29(4):501–7.CrossRefPubMed Soresina A, Nacinovich R, Bomba M, Cassani M, Molinaro A, Sciotto A, et al. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol. 2009;29(4):501–7.CrossRefPubMed
11.
go back to reference Lederman HM, Winkelstein J a. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore). 1985;64(3):145–56.CrossRef Lederman HM, Winkelstein J a. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore). 1985;64(3):145–56.CrossRef
12.
go back to reference Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.CrossRefPubMed Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.CrossRefPubMed
13.
go back to reference Winkelstein J a, Conley ME, James C, Howard V, Boyle JM. Status of adults with X-linked agammaglobulinemia. Med. 2010;9(2):1–14. Winkelstein J a, Conley ME, James C, Howard V, Boyle JM. Status of adults with X-linked agammaglobulinemia. Med. 2010;9(2):1–14.
14.
go back to reference Quartier P, Debré M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134(5):589–96.CrossRefPubMed Quartier P, Debré M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134(5):589–96.CrossRefPubMed
15.
go back to reference Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Clin Immunol. 1999;93(3):190–7.CrossRefPubMed Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Clin Immunol. 1999;93(3):190–7.CrossRefPubMed
16.
go back to reference Rozas CJ, Goldman AL. Daily spirometric variability: normal subjects and subjects with chronic bronchitis with and without airflow obstruction. Arch Intern Med. 1982;142(7):1287–91.CrossRefPubMed Rozas CJ, Goldman AL. Daily spirometric variability: normal subjects and subjects with chronic bronchitis with and without airflow obstruction. Arch Intern Med. 1982;142(7):1287–91.CrossRefPubMed
17.
go back to reference Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.CrossRefPubMedPubMedCentral Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.CrossRefPubMedPubMedCentral
18.
go back to reference Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. Respir Med. 1991;85 Suppl B:25–31. discussion 33–7.CrossRefPubMed Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. Respir Med. 1991;85 Suppl B:25–31. discussion 33–7.CrossRefPubMed
19.
go back to reference Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Validation of the St. George’s respiratory questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997;156(2):536–41.CrossRefPubMed Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Validation of the St. George’s respiratory questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997;156(2):536–41.CrossRefPubMed
21.
go back to reference Hurst JR, Workman S, Garcha DS, Seneviratne SL, Haddock J a, Grimbacher B. Activity, severity and impact of respiratory disease in primary antibody deficiency syndromes. J Clin Immunol. 2014;34(1):68–75.CrossRefPubMed Hurst JR, Workman S, Garcha DS, Seneviratne SL, Haddock J a, Grimbacher B. Activity, severity and impact of respiratory disease in primary antibody deficiency syndromes. J Clin Immunol. 2014;34(1):68–75.CrossRefPubMed
22.
go back to reference Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, Vilagut G, et al. Interpretation of quality of life scores from the St George’s respiratory questionnaire. Eur Respir J. 2002;19(3):405–13.CrossRefPubMed Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, Vilagut G, et al. Interpretation of quality of life scores from the St George’s respiratory questionnaire. Eur Respir J. 2002;19(3):405–13.CrossRefPubMed
23.
go back to reference McHorney C a, Ware JE, Raczek a E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–63.CrossRefPubMed McHorney C a, Ware JE, Raczek a E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–63.CrossRefPubMed
24.
go back to reference Aghamohammadi A, Montazeri A, Abolhassani H, Saroukhani S, Pourjabbar S, Tavassoli M, et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol. 2011;10(1):47–51.PubMed Aghamohammadi A, Montazeri A, Abolhassani H, Saroukhani S, Pourjabbar S, Tavassoli M, et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol. 2011;10(1):47–51.PubMed
25.
go back to reference Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53(1):46–50.CrossRefPubMedPubMedCentral Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53(1):46–50.CrossRefPubMedPubMedCentral
26.
27.
go back to reference Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol. 2000;19(2):183–204.CrossRefPubMed Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol. 2000;19(2):183–204.CrossRefPubMed
28.
go back to reference Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6(1):1–10.CrossRefPubMedPubMedCentral Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6(1):1–10.CrossRefPubMedPubMedCentral
30.
go back to reference Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60.e4.CrossRefPubMed Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60.e4.CrossRefPubMed
31.
go back to reference Lucas M, Lee M, Oksenhendler E, Chapel H. The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies. J Allergy Clin Immunol Pract. Elsevier; 2015;3(6):998–1000.e2. Lucas M, Lee M, Oksenhendler E, Chapel H. The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies. J Allergy Clin Immunol Pract. Elsevier; 2015;3(6):998–1000.e2.
32.
go back to reference Kainulainen L, Varpula M, Liippo K, Svedström E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031–6.CrossRefPubMed Kainulainen L, Varpula M, Liippo K, Svedström E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031–6.CrossRefPubMed
33.
go back to reference Titman P, Allwood Z, Gilmour C, Malcolmson C, Duran-Persson C, Cale C, et al. Quality of life in children with primary antibody deficiency. J Clin Immunol. 2014;34(7):844–52.CrossRefPubMedPubMedCentral Titman P, Allwood Z, Gilmour C, Malcolmson C, Duran-Persson C, Cale C, et al. Quality of life in children with primary antibody deficiency. J Clin Immunol. 2014;34(7):844–52.CrossRefPubMedPubMedCentral
34.
go back to reference Howard V, Myers L a, Williams D a, Wheeler G, Turner EV, Cunningham JM. Stem cell transplants for patients with X-linked agammaglobulinemia. Clin Immunol. 2003;107(2):98–102.CrossRefPubMed Howard V, Myers L a, Williams D a, Wheeler G, Turner EV, Cunningham JM. Stem cell transplants for patients with X-linked agammaglobulinemia. Clin Immunol. 2003;107(2):98–102.CrossRefPubMed
35.
go back to reference Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets. 2011;8222(December 2015):9–18. Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets. 2011;8222(December 2015):9–18.
36.
go back to reference Yel L, Rabbat CJ, Cunningham-Rundles C, Orange JS, Torgerson TR, Verbsky JW, et al. A novel targeted screening tool for hypogammaglobulinemia: measurement of serum immunoglobulin (IgG, IgM, IgA) levels from dried blood spots (Ig-DBS assay). J Clin Immunol. 2015;35(6):573–82.CrossRefPubMedPubMedCentral Yel L, Rabbat CJ, Cunningham-Rundles C, Orange JS, Torgerson TR, Verbsky JW, et al. A novel targeted screening tool for hypogammaglobulinemia: measurement of serum immunoglobulin (IgG, IgM, IgA) levels from dried blood spots (Ig-DBS assay). J Clin Immunol. 2015;35(6):573–82.CrossRefPubMedPubMedCentral
Metadata
Title
Respiratory Health and Related Quality of Life in Patients with Congenital Agammaglobulinemia in the Northern Region of the UK
Authors
Branwen A. Bryan
Alex Battersby
Benjamin Martin James Shillitoe
Dawn Barge
Helen Bourne
Terry Flood
Andrew J. Cant
Catherine Stroud
Andrew R. Gennery
Publication date
01-07-2016
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2016
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-016-0284-3

Other articles of this Issue 5/2016

Journal of Clinical Immunology 5/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.